Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Annals of Oncology

• Publication date

  2007-10-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdm565PMID 18178958
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.

  2007cited by this paper
• Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma

  2006cited by this paper
• Targeted therapy for metastatic renal cell carcinoma.

  2006cited by this paper
• Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

  2006cited by this paper
• A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma

  2006cited by this paper
• Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

  2006cited by this paper
• Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.

  2006cited by this paper
• Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma

  2006cited by this paper
• Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma

  2006cited by this paper
• Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma.

  2006cited by this paper
• Synergistic effect and condition of pegylated interferon α with paclitaxel on glioblastoma

  2006cited by this paper
• Phase II study of temozolomide plus pegylated interferon‐α‐2b for metastatic melanoma

  2006cited by this paper
• Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.

  2005influential reference
• Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha.

  2005cited by this paper
• Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.

  2004cited by this paper
• Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study

  2004cited by this paper
• Clinical and Laboratory Investigations Temozolomide and interferon a2b in metastatic melanoma stage IV

  2004cited by this paper
• Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup

  2004cited by this paper
• Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

  2003cited by this paper
• Temozolomide in combination with interferon α‐2b in patients with metastatic melanoma

  2003cited by this paper
• Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.

  2003cited by this paper
• Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.

  2003influential reference
• Pegylated interferons for the treatment of chronic hepatitis C infection.

  2002cited by this paper
• Treating cancer with PEG Intron

  2002cited by this paper
• Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

  2002cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

  2000cited by this paper
• [Phase III study].

  1995cited by this paper

• Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells

  2024cites this paper
• 30 years German Dermatologic Cooperative Oncology Group (DeCOG)

  2021cites this paper
• 30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

  2021cites this paper
• Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma

  2020cites this paper
• Freeze-thaw electrospun PVA-dacarbazine nanoparticles: preparation, characterization and anticancer evaluation

  2020cites this paper
• Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy.

  2019cites this paper
• Temozolomide for Treating Malignant Melanoma.

  2015cites this paper
• Systemic treatments for metastatic cutaneous melanoma.

  2014cites this paper
• In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.

  2014cites this paper
• ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)

  2013cites this paper
• Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

  2013cites this paper
• A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours

  2013cites this paper
• Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.

  2013cites this paper
• Immunotherapy for malignant melanoma.

  2012cites this paper
• Formulation of Dacarbazine-loaded Cubosomes. Part III. Physicochemical Characterization

  2010cites this paper
• Systemic therapy for cutaneous melanoma.

  2010cites this paper
• MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

  2010cites this paper
• New research advances for treating metastatic melanoma

  2010cites this paper
• Immunotherapy for Melanoma: Current Status and Perspectives

  2010cites this paper
• Investigation of response and resistance to dasatinib in melanoma cell lines

  2010cites this paper
• Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.

  2010cites this paper
• Childhood melanoma.

  2009cites this paper
• Immunotherapy of distant metastatic disease

  2009cites this paper
• Formulation of Dacarbazine-Loaded Cubosomes—Part I: Influence of Formulation Variables

  2009cites this paper
• Long-term pegylated interferon- α and its potential in the treatment of melanoma

  2009influential citation
• Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma

  2009cites this paper
• Long-term pegylated interferon-α and its potential in the treatment of melanoma

  2009influential citation
• PEG conjugates in clinical development or use as anticancer agents: an overview.

  2009cites this paper
• Long-term pegylated interferon- α and its potential in the treatment of melanoma

  2009influential citation
• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cites this paper